This will be decidedly good news.
More in a moment, but Here's the bit, from the overnight press release:
. . . .Merck today announced that studies involving KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in 12 different types of cancer will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain, Sept. 8-12. In total, 35 abstracts – including data from studies investigating the use of KEYTRUDA as monotherapy and in novel combinations – were accepted for presentation at the congress, including five late-breaking abstracts. Data to be presented include studies of KEYTRUDA as monotherapy in advanced urothelial (bladder) carcinoma, gastric cancer, head and neck squamous cell carcinoma (HNSCC), microsatellite instability-high (MSI-H) or mismatch repair deficient cancer and triple-negative breast cancer (TNBC), as well as studies of KEYTRUDA in combination with other therapies in advanced non-small cell lung cancer (NSCLC), gastric cancer and melanoma.
Merck’s broad KEYTRUDA clinical development program includes more than 30 tumor types in more than 550 clinical trials, including more than 300 trials that combine KEYTRUDA with other cancer treatments. . . .
Onward, grinning just as at right -- for entirely unrelated reasons. . . smile.
नमस्ते
No comments:
Post a Comment